Filippo Ciceri
Barcelona, CT, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Phenotype and psychometric characterization of Phelan-McDermid syndrome patients: pioneering towards personalized medicine.
Journal: Frontiers in psychiatry
Published: October 15, 2024
Therapeutic targeting of EP300/CBP by bromodomain inhibition in hematologic malignancies.
Journal: Cancer cell
Published: July 08, 2022
Chemoprobe-based assays of histone lysine demethylase 1A target occupation enable in vivo pharmacokinetics and pharmacodynamics studies of KDM1A inhibitors.
Journal: The Journal of biological chemistry
Published: December 05, 2018
Oral administration of the LSD1 inhibitor ORY-3001 increases fetal hemoglobin in sickle cell mice and baboons.
Journal: Experimental hematology
Published: June 27, 2018
ORY-1001, a Potent and Selective Covalent KDM1A Inhibitor, for the Treatment of Acute Leukemia.
Journal: Cancer cell
Published: May 19, 2017
Understanding Epigenetic Alterations in Alzheimer's and Parkinson's Disease: Towards Targeted Biomarkers and Therapies.
Journal: Current pharmaceutical design
Published: January 26, 2017
The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells.
Journal: Cancer cell
Published: October 24, 2011
Showing 1-9 of 9
Last Updated: 09/26/2026